Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

NGNatalie GalaninaATAung TinCGCassandra Gillespie

Discussion

Loading...

Member takes

Overview

Real-world analysis demonstrates risk stratification via circulating tumor DNA in B-cell and T-cell lymphomas, indicating potential for personalized monitoring.

Key Points

  • ctDNA serves as a potent biomarker, correlating with event-free survival in lymphomas and highlighting its utility for risk stratification.
  • Detecting circulating tumor DNA showed a strong prognostic relationship in B-cell lymphomas, especially for aggressive subtypes like DLBCL.
  • The retrospective analysis included a diverse cohort of 148 lymphoma patients, ensuring broad applicability of findings across subtypes.
  • Results suggest that consistent monitoring of ctDNA may aid early recurrence detection and improve treatment strategies for patients.

Cite This Study

Galanina et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d708https://doi.org/10.1182/blood-2025-281
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL)2025
  2. 2Dynamic Profiling of Cell Free Tumour DNA in Aggressive B‐Cell Lymphoma From Diagnosis to Transformation at Relapse2025 · 1 citations
  3. 3Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring2026
  4. 4Integration of longitudinal ctdna MRD and PET/CT enhances prognostic stratification in newly diagnosed diffuse large B-cell lymphoma: A prospective multicenter study2025
  5. 5Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.2025